Abstract
Severe acute lung injury is a rare but life-threatening complication associated with bortezomib. We report a patient with multiple myeloma who developed a severe diffuse alveolar hemorrhage (DAH) immediately after the first bortezomib administration. The patient was suspected to have pulmonary involvement of myeloma, which caused DAH after rapidly eradicating myeloma cells in the lungs with bortezomib. Rechallenge with bortezomib was performed without recurrent DAH. In patients with multiple myeloma who manifest abnormal pulmonary shadow, we should be aware of early-onset severe DAH after bortezomib administration, which might be due to pulmonary involvement of myeloma cells.
Cite
CITATION STYLE
Sugita, Y., Ohwada, C., Nagao, Y., Kawajiri, C., Shimizu, R., Togasaki, E., … Nakaseko, C. (2015). Early-Onset Severe Diffuse Alveolar Hemorrhage after Bortezomib Administration Suggestive of Pulmonary Involvement of Myeloma Cells. Journal of Clinical and Experimental Hematopathology : JCEH, 55(3), 163–168. https://doi.org/10.3960/jslrt.55.163
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.